Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06, Zacks reports. During the same period in the prior year, the company earned ($0.24) earnings per share.
Acurx Pharmaceuticals Trading Down 1.6 %
Shares of ACXP stock opened at $1.82 on Thursday. The stock has a market capitalization of $29.58 million, a price-to-earnings ratio of -1.67 and a beta of -1.73. Acurx Pharmaceuticals has a 12-month low of $1.52 and a 12-month high of $5.28. The stock’s 50-day moving average price is $1.97 and its 200-day moving average price is $2.14.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Acurx Pharmaceuticals in a research report on Monday, August 12th.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Read More
- Five stocks we like better than Acurx Pharmaceuticals
- 3 REITs to Buy and Hold for the Long Term
- Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?”
- 5 Top Rated Dividend Stocks to Consider
- Unusual Trading Volume in Gerdau: A Signal for Buyers?
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Stocks Gaining Traction in Their Turnaround Stories
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
